Synthomer Divests William Blythe to Focus on Specialty Chemicals

Synthomer ( (GB:SYNT) ) has issued an announcement.

Synthomer plc announced the divestment of its inorganic chemistry business, William Blythe Limited, to its management team and H2 Equity Partners for £30 million. This strategic move is part of Synthomer’s efforts to streamline operations and focus on high-growth specialty chemicals markets, reducing complexity and enhancing its leadership in these areas. The divestment is expected to complete by the end of May 2025, with proceeds aimed at reducing the Group’s net debt, marking a significant step in Synthomer’s strategic realignment.

Spark’s Take on GB:SYNT Stock

According to Spark, TipRanks’ AI Analyst, GB:SYNT is a Neutral.

Synthomer’s overall stock score is low due to significant financial and technical challenges. The company faces profitability and cash flow issues, reflected in its financial statements and negative market momentum. Although there are positive corporate actions indicating management confidence, they are overshadowed by broader financial and market difficulties. The stock’s unattractive valuation further weighs down the score.

To see Spark’s full report on GB:SYNT stock, click here.

More about Synthomer

Synthomer plc is a leading supplier of high-performance, highly specialised polymers and ingredients, serving key sectors such as coatings, construction, adhesives, and health and protection. Headquartered in London, UK, and listed since 1971, Synthomer operates with approximately 4,000 employees across five innovation centres and 31 manufacturing sites globally. The company focuses on creating innovative and sustainable solutions, with a significant portion of its sales from new and patent-protected products, aligning with global megatrends and sustainability goals.

YTD Price Performance: -42.24%

Average Trading Volume: 797,904

Technical Sentiment Signal: Buy

Current Market Cap: £152.1M

For an in-depth examination of SYNT stock, go to TipRanks’ Stock Analysis page.